虚拟现实回忆疗法在痴呆症护理中:研究范围的综述
1CYENS Centre of Excellence, Lellou Demetriades, Plateia Dimarchou 1, Nicosia, 1016, Cyprus, 357 22 747575.
JMIR XR and spatial computing
|December 4, 2025
概括
虚拟现实回忆疗法 (VR-RT) 对痴呆症患者来说是可行的,它可以改善情绪和社交互动,副作用最小. 高成本和培训需求是这种创新的痴呆症护理方法的关键实施挑战.
科学领域:
- 老年学是一门学科.
- 神经学 神经学
- 人与计算机的交互
背景情况:
- 痴呆症显著影响认知和社会功能,为患者和护理人员带来挑战.
- 传统的痴呆症治疗可能会产生不良影响,强调需要非药物干预措施,如回忆疗法 (RT).
- 虚拟现实 (VR) 提供沉浸式体验,以刺激记忆,改善情绪健康,并减少痴呆症护理中的行为症状.
研究的目的:
- 进行范围审查,评估通过虚拟现实 (VR) 在痴呆症护理中提供回忆疗法 (RT) 的可行性和实施挑战.
- 检查使用的VR系统类型,它们的治疗益处,以及对痴呆症RT的采用障碍.
主要方法:
- 在五个电子数据库 (谷歌学者,ACM数字图书馆,IEEE Xplore,MEDLINE,PubMed) 进行了系统的搜索.
- 包括在2000年至2025年间发表的研究,调查痴呆症患者RT的VR.
- 根据PRISMA-ScR指南提取数据,并根据可行性,VR系统类型,治疗效果和实施考虑因素进行主题分析.
主要成果:
- 十五项研究符合纳入标准,表明VR是可行的,并且被痴呆症患者接受,参与度很高,副作用很少.
- 完全沉浸式VR系统 (头部显示器) 是最常见的,而半沉浸式系统提供了一个具有成本效益的替代方案.
- VR-RT改善了回忆力,情绪和社交互动,尽管认知效应仍然没有确定性. 实施障碍包括成本,基础设施限制和护理人员培训需求.
结论:
- 虚拟现实回忆疗法 (VR-RT) 显示出作为痴呆症护理先进的非药物干预的前景.
- 未来的研究应该优先考虑具有成本效益,可扩展的VR解决方案,个性化的体验和结构化的护理人员培训计划.
- 与传统回忆疗法相比,长度研究对于确定VR-RT的长期疗效至关重要.
相关概念视频
Cognitive Development During Adulthood
749
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
749
Dementia
487
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
487
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764


